Business
Bone Biologics is a medical-device company focused on bone regeneration in spinal fusion using NELL-1 with demineralized bone matrix.
Bone Biologics narrowed losses, improved cash from ops, and grew equity, but remained pre-revenue.
The read at a glance✓ Audited against SEC data
- Business mix — Bone-regeneration device candidateNote
- Revenue — No revenue reportedNote
- Losses — Net loss narrowed 24.4%OK
- Cash — Cash from ops improvedOK
- Balance sheet — Equity rose 54.4%OK
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman-Z, Beneish-M, and earnings-quality unavailableNote
Leadership changes
From Bone Biologics Corp's own filings, the day they're filed.
- Phillip Meikle · directors · appointmenteff. 2024-10-16
- Don Hankey · director · departureeff. 2024-10-01
- Erick Lucera · Directors · departureeff. 2023-12-27
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-07-09
- DEF 14A · Annual proxy (pay & governance)2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bone Biologics Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.